ES2184106T3 - Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas. - Google Patents
Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.Info
- Publication number
- ES2184106T3 ES2184106T3 ES97930203T ES97930203T ES2184106T3 ES 2184106 T3 ES2184106 T3 ES 2184106T3 ES 97930203 T ES97930203 T ES 97930203T ES 97930203 T ES97930203 T ES 97930203T ES 2184106 T3 ES2184106 T3 ES 2184106T3
- Authority
- ES
- Spain
- Prior art keywords
- derivative
- hyperproduction
- cytokines
- peripheral
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 230000002093 peripheral effect Effects 0.000 title 1
- 210000001428 peripheral nervous system Anatomy 0.000 title 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical compound C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005544 indolocarbazole Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
EN LA PRESENTE INVENCION SE PRESENTAN METODOLOGIAS TERAPEUTICAS EN LAS QUE SE HACE USO DE UN DERIVADO SUSTITUIDO POR ANILLOS DEL INDOLCARBAZOL K252A, QUEDANDO EL DERIVADO REPRESENTADO POR LA FORMULA (A). EL COMPUESTO ES UTIL EN EL TRATAMIENTO DE NEUROPATIAS PERIFERICAS, DEGENERACION DEL SISTEMA NERVIOSO CENTRAL Y SUPERPRODUCCION DE CITOQUINAS. LAS ENFERMEDADES TIPICAS RELACIONADAS CON LAS ANTERIORES SON LA NEUROPATIA PERIFERICA, LA ENFERMEDAD DE ALZHEIMER, LA ENFERMEDAD DE PARKINSON Y LAS CONDICIONES AUTOINMUNES Y ALERGICAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2040696P | 1996-06-25 | 1996-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2184106T3 true ES2184106T3 (es) | 2003-04-01 |
Family
ID=21798468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97930203T Expired - Lifetime ES2184106T3 (es) | 1996-06-25 | 1997-06-24 | Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6184217B1 (es) |
EP (1) | EP0912184B1 (es) |
JP (2) | JP2000514420A (es) |
CN (1) | CN1108799C (es) |
AT (1) | ATE224718T1 (es) |
AU (1) | AU721942B2 (es) |
BR (1) | BR9710693A (es) |
DE (1) | DE69715862T2 (es) |
DK (1) | DK0912184T3 (es) |
ES (1) | ES2184106T3 (es) |
HK (1) | HK1018745A1 (es) |
NO (1) | NO317335B1 (es) |
NZ (1) | NZ333441A (es) |
PT (1) | PT912184E (es) |
RU (1) | RU2183959C2 (es) |
UA (1) | UA65542C2 (es) |
WO (1) | WO1997049406A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
NZ511024A (en) | 1998-09-25 | 2003-10-31 | Cephalon Inc | Methods for preventing/treating damage to sensory hair cells, loss of hearing and cochlear neurons using fused pyrrolocarbazoles |
WO2000021531A1 (fr) | 1998-10-13 | 2000-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Medicaments pour maladies oculaires |
JP2000290184A (ja) * | 1999-04-01 | 2000-10-17 | Kyowa Hakko Kogyo Co Ltd | 経鼻投与製剤 |
WO2001051046A1 (en) * | 2000-01-14 | 2001-07-19 | University Of Virginia Patent Foundation | Airway alkalinization as therapy for airway diseases |
AU2001261324A1 (en) * | 2000-05-08 | 2001-11-20 | Psoriasis Research Institute | Psoriasis treatment |
US7129250B2 (en) | 2000-05-19 | 2006-10-31 | Aegera Therapeutics Inc. | Neuroprotective and anti-proliferative compounds |
AR035971A1 (es) * | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
AU2003300397A1 (en) * | 2002-12-23 | 2004-07-22 | Rinat Neuroscience Corp. | Methods for treating taxol-induced sensory neuropathy |
PL378582A1 (pl) | 2003-03-19 | 2006-05-02 | Biogen Idec Ma Inc. | Białko wiążące receptor Nogo |
US20070014786A1 (en) * | 2003-03-20 | 2007-01-18 | Rinat Neuroscience Corp. | Methods for treating taxol-induced gut disorder |
TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
WO2005007144A2 (en) * | 2003-07-14 | 2005-01-27 | Decode Genetics Ehf | Method of diagnosis and treatment for asthma based on haplotype association |
EP1653972A1 (en) * | 2003-07-23 | 2006-05-10 | Creabilis Therapeutics s.r.l. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
CA2557371C (en) | 2004-02-27 | 2012-09-25 | H. Lundbeck A/S | Crystalline forms of a pharmaceutical compound |
AU2005258335B2 (en) | 2004-06-24 | 2011-03-17 | Biogen Ma Inc. | Treatment of conditions involving demyelination |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
US8642040B2 (en) | 2006-07-24 | 2014-02-04 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6041489A (ja) * | 1983-08-12 | 1985-03-05 | Kyowa Hakko Kogyo Co Ltd | 新規生理活性物質k―252 |
US4554402A (en) | 1983-12-23 | 1985-11-19 | Aluminum Company Of America | Vibration damper for overhead conductor |
JPS62120388A (ja) | 1985-11-19 | 1987-06-01 | Meiji Seika Kaisha Ltd | Sf−2370物質ハロゲン化誘導体とその製造法 |
JPS62155285A (ja) | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
JPS62155284A (ja) | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
JPS62220196A (ja) | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ucn―01 |
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
JPH0826036B2 (ja) | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US4735939A (en) | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
WO1988007045A1 (en) | 1987-03-09 | 1988-09-22 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
WO1989007105A1 (en) | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
DE3835842A1 (de) | 1988-10-21 | 1990-04-26 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
DE3924538A1 (de) | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
WO1991009034A1 (en) | 1989-12-14 | 1991-06-27 | Schering Corporation | Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856 |
JPH0586068A (ja) | 1991-03-04 | 1993-04-06 | Rikagaku Kenkyusho | 新規抗生物質rk−1409、その製造法並びに抗腫瘍剤及び抗炎症剤 |
CA2123096A1 (en) | 1991-11-08 | 1993-05-13 | Beat J. Knusel | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
JP2593021B2 (ja) | 1991-12-13 | 1997-03-19 | 伊藤ハム株式会社 | ウシ胚の性の識別方法 |
US6271242B1 (en) | 1992-02-10 | 2001-08-07 | Bristol-Myers Squibb Co. | Method for treating cancer using a tyrosine protein kinase inhibitor |
JPH05247055A (ja) | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
JPH0673063A (ja) | 1992-06-22 | 1994-03-15 | Kyowa Hakko Kogyo Co Ltd | Ucn−01誘導体 |
ES2136103T3 (es) | 1992-06-22 | 1999-11-16 | Kyowa Hakko Kogyo Kk | Procedimiento para la preparacion de derivados de estaurosporina. |
US5461146A (en) | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
GB9215921D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Anti-inflammatory compounds |
ATE165097T1 (de) | 1993-05-28 | 1998-05-15 | Cephalon Inc | Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen |
JPH08511785A (ja) | 1993-06-17 | 1996-12-10 | チバ−ガイギー アクチェンゲゼルシャフト | プロテインキナーゼc阻害剤として有用なインドロカルバゾール |
WO1995022331A1 (en) | 1994-02-18 | 1995-08-24 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
-
1997
- 1997-06-24 BR BR9710693-3A patent/BR9710693A/pt not_active IP Right Cessation
- 1997-06-24 WO PCT/US1997/010898 patent/WO1997049406A1/en active IP Right Grant
- 1997-06-24 RU RU99101117/14A patent/RU2183959C2/ru active
- 1997-06-24 EP EP97930203A patent/EP0912184B1/en not_active Expired - Lifetime
- 1997-06-24 JP JP10503444A patent/JP2000514420A/ja active Pending
- 1997-06-24 PT PT97930203T patent/PT912184E/pt unknown
- 1997-06-24 DE DE69715862T patent/DE69715862T2/de not_active Expired - Lifetime
- 1997-06-24 AU AU34090/97A patent/AU721942B2/en not_active Expired
- 1997-06-24 DK DK97930203T patent/DK0912184T3/da active
- 1997-06-24 CN CN97197341A patent/CN1108799C/zh not_active Expired - Lifetime
- 1997-06-24 NZ NZ333441A patent/NZ333441A/xx not_active IP Right Cessation
- 1997-06-24 US US08/881,679 patent/US6184217B1/en not_active Expired - Lifetime
- 1997-06-24 AT AT97930203T patent/ATE224718T1/de active
- 1997-06-24 ES ES97930203T patent/ES2184106T3/es not_active Expired - Lifetime
- 1997-06-24 UA UA99010342A patent/UA65542C2/uk unknown
-
1998
- 1998-12-23 NO NO19986111A patent/NO317335B1/no not_active IP Right Cessation
-
1999
- 1999-09-02 HK HK99103811A patent/HK1018745A1/xx not_active IP Right Cessation
-
2008
- 2008-03-04 JP JP2008053174A patent/JP4767982B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE224718T1 (de) | 2002-10-15 |
RU2183959C2 (ru) | 2002-06-27 |
EP0912184A1 (en) | 1999-05-06 |
JP2000514420A (ja) | 2000-10-31 |
HK1018745A1 (en) | 2000-01-07 |
EP0912184B1 (en) | 2002-09-25 |
UA65542C2 (uk) | 2004-04-15 |
JP2008189676A (ja) | 2008-08-21 |
US6184217B1 (en) | 2001-02-06 |
AU3409097A (en) | 1998-01-14 |
WO1997049406A1 (en) | 1997-12-31 |
AU721942B2 (en) | 2000-07-20 |
CN1228024A (zh) | 1999-09-08 |
DE69715862T2 (de) | 2003-04-10 |
CN1108799C (zh) | 2003-05-21 |
NO986111L (no) | 1999-02-23 |
NO986111D0 (no) | 1998-12-23 |
PT912184E (pt) | 2002-12-31 |
NZ333441A (en) | 1999-05-28 |
BR9710693A (pt) | 2000-01-11 |
JP4767982B2 (ja) | 2011-09-07 |
DE69715862D1 (de) | 2002-10-31 |
NO317335B1 (no) | 2004-10-11 |
DK0912184T3 (da) | 2002-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2184106T3 (es) | Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas. | |
DE69510940T2 (de) | Pyrazolo und pyrrolopyridine | |
ZA9710796B (en) | Oxyiminopregnanecarbolactones. | |
ES2132223T3 (es) | Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4. | |
EA200200742A1 (ru) | 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии | |
DK0520200T3 (da) | Imadazol-forbindelser, deres fremstilling og anvendelse | |
ES2170798T3 (es) | Benzopiranos y su uso como agentes terapeuticos. | |
ES2153842T3 (es) | Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central. | |
DE69604071D1 (de) | Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung | |
LV11940A (lv) | Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas | |
ES2144857T3 (es) | Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso. | |
NO970185L (no) | Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi | |
ES1034986Y (es) | Aparato para el tratamiento del cuerpo humano. | |
ES2066897T3 (es) | 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida. | |
ES2163717T3 (es) | Derivados de pirrolidinona y su uso como medicamentos antipsicoticos. | |
ES2168240T1 (es) | Uso de efectores del sistema nervioso central colinergico para el tratamiento del delirio. | |
MX9204896A (es) | Tiazepinas substituidas como agentes del sistema nervioso central. | |
DE336326T1 (de) | 3-aminodihydrothiophen-2-on peptid-derivate, prozesse fuer ihre herstellung und therapeutische anwendung. | |
AR021502A1 (es) | Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso | |
ES2167942T3 (es) | Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes. | |
ES1030328Y (es) | Estructura movil del plano-lecho de la cama. | |
IT227969Y1 (it) | Armatura tubolare ad espansione per il presidio terapeutico della dissezione aortica, perfezionata. | |
ES2076107B1 (es) | Derivados de antibioticos macrolidos de anillos de 16 miembros. | |
ES1040026Y (es) | Dispositivo de aireacion del cuerpo humano. | |
UA33498A (uk) | Спосіб лікування терапевтично резистентних форм шизофренії |